Despite declining OUS results, the US Trauma Market experienced healthy growth attributed to adoption of new products.
Among the many topics covered in detail in our comprehensive Q322 Trauma Market Recap* are:
- Complete Q322 Trauma Market Overview and Highlights
- SmartTRAK's Expert Market Analysis and Insights
- All Company News, Revenues, Data, Charts and Shares
- Foreign Currency Headwinds
- International Market Dynamics
- US Finishes the Quarter with Healthy Gains
- Q322 Trauma Regulatory Highlights
While procedural volumes continued to strengthen, so did foreign currency headwinds in Q322. The mounting headwinds negatively impacted reported revenue growth for most companies in markets outside the US, while Global companies with a strong international presence were ...
Read the entire Q322 Trauma Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*
*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK is a comprehensive, easy-to-use, business intelligence solution for the Life Sciences Industry that provides breaking updates on pertinent company news, potential treatments and guidance, international survey results, statistical analysis by country, studies, trial results, financial impact and more. All subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK, just click here.
